PlainPharmaWatch

CMS Open Payments · Program Year 2024

Brixton Biosciences, Inc.

Brixton Biosciences, Inc. reported $117,550.37 across General Payments, Research, and Ownership to 72 physicians and teaching hospitals across 93 transactions.

See the rankings → How this is sourced
$117.6K
All-tracks total
93
Transactions
72
Recipients
#1143
of 1,925 companies

Brixton Biosciences, Inc. reported $117,550.37 across all CMS Open Payments tracks (General + Research + Ownership) to 72 physicians and teaching hospitals in Program Year 2024 - ranking #1143 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $36,385.37, averaging $1.6K per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer brixton-biosciences-inc Brixton Biosciences, Inc.

$117.6K · #1143/1,925 · 0.0% industry · PY2024

  • TOT $117.6K
  • RANK #1143
  • SHARE 0.0%
  • TXN 93
  • RCP 72
  • CAT 3
  • GEN $36.4K
  • TOP1 33.5%
  • PY 2024

Volume peers

Nearest volume peer: Jan Medical Inc. ($117.5K)

Forte Bio-Pharma LLC$118.4KBrixton Biosciences, Inc. (t…$117.6KJan Medical Inc.$117.5KCaldera Medical, Inc$117.1KReprise Biomedical, Inc.$117.0K
All-tracks payment totals near Brixton Biosciences, Inc. (CMS Open Payments PY2024)

Brixton Biosciences, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

What the Data Shows for Brixton Biosciences, Inc.

Brixton Biosciences, Inc. ranks #1143 out of 1,925 companies in the CMS Open Payments database for Program Year 2024, a comparatively small 0.0% slice of all industry payments reported nationwide for the year. The underlying total is $117,550.37 across 93 transactions to 72 physicians and teaching hospitals - $1.3K per transaction and $1.6K per recipient on average.

Of the 3 general-payment categories charted below, "Consulting Fee" is the largest at $30.4K across 15 transactions, 83.7% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

"Consulting Fee" leads Brixton Biosciences, Inc.'s 3-category general-payment breakdown at $30.4K, 83.7% of the reported total.

How Brixton Biosciences, Inc. divides its payments

Ranked by total dollars reported per category

1. Consulting Fee$30.4K2. Food and Beverage$5.0K3. Travel and Lodging$924.50
Payment Type Amount Transactions
Consulting Fee $30.4K 15
Food and Beverage $5.0K 52
Travel and Lodging $924.50 5

Recipient Concentration in General Payments

The five largest recipient relationships account for $26,900.83 (73.9%) of $36,385.37 in this company's General Payments records across 38 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Brixton Biosciences, Inc.

The five named recipients with the highest reported General Payments from this company

Maxim Eckmann$12.2KAnis Dizdarevic$7.5KRobert Roberts$3.1KBrian Fuller$2.1KIan Valerio$2.0K
  1. 1

    Maxim Eckmann

    $12,183.09 across 9 reported transactions

  2. 2

    Anis Dizdarevic

    $7,500.00 across 5 reported transactions

  3. 3

    Robert Roberts

    $3,088.55 across 1 reported transactions

  4. 4

    Brian Fuller

    $2,129.19 across 2 reported transactions

  5. 5

    Ian Valerio

    $2,000.00 across 1 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Brixton Biosciences, Inc.'s, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Brixton Biosciences, Inc..

Sysmex America, Inc.

HHI 1755

bluebird bio, Inc.

HHI 1750

Pfizer International LLC

HHI 1747

NextStep Arthropedix, LLC

HHI 1747

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Brixton Biosciences, Inc..

Showing 6 of 1,924 companies with CMS-reported payment data.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Brixton Biosciences, Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.